A new study by UK Markey Cancer Center researchers shows that DACH1 mutations are prevalent in Kentucky patients with endometrial cancer, suggesting that DACH1 may be a candidate biomarker for future trials with immunotherapy.
A major initiative of Williams and the Markey Community Impact Office will be the organization and expansion of Markey’s research and outreach portfolio that is focused on reducing cancer and other health disparities based on race/ethnicity, socioeconomic status, etc.
Building on these findings, Plattner and Markey oncologists are now collaborating with the pharmaceutical company Novartis to develop a Phase I clinical trial to test the safety and effectiveness of using nilotinib in relapsed melanoma patients.
Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
Recently published in PLOS One, the study used Kentucky Cancer Registry patient data from 2007-2011 to identify trends in epidermal growth factor receptor (EGFR) mutation testing and the usage of the EGFR inhibitor, erlotinib.
In 2018, Vanderford was also named a recipient of the SRAI Mid-Career Level Excellence Award. Vanderford also serves as assistant director for research at the UK Markey Cancer Center, where he oversees a special oncology training program for Appalachian students, ACTION.
Artemisia annua or "Sweet Annie" has been used as a medicinal herb for centuries. With potential to treat a variety of cancers & even COVID-19, this plant is more relevant than ever & UK is showing how we can take it from Kentucky fields to the lab to our patients.
As a cancer prevention researcher trained in both basic laboratory science and epidemiology, Kuhs’ experience allows her to apply basic science findings to population-based studies, which will be essential to lowering cancer rates in the hardest-hit areas of the state.
Kentucky has one of the nation's highest incidences of oral cancer, according to the National Institutes of Health, and the prevalence of oral cancer in the targeted counties is as much as 54% higher than the state average.
A group led by the Markey Cancer Center researcher Qing-Bai She discovered that SMS is overexpressed in colorectal cancers and plays an important role in balancing cellular spermidine levels that are a necessary adaptation for colorectal cancer growth.